custom image

Advances in Cancer Immunotherapy

August 17–19, 2020  |  11:00–6:00PM ET  |  #VKScancerimmuno20

Cancer immunotherapy by blocking immune inhibitory checkpoints or engineering T cells for adoptive cell transfer is providing an unprecedented level of long-term antitumor activity in patients with several metastatic cancers. However, the majority of patients with advanced cancers still do not experience sustained clinical benefit from immunotherapy. Understanding the mechanistic basis of response and resistance to these therapies and how therapeutic approaches could best be combined will be essential to continue progress. The largest human experiment is currently being conducted with over 1,000 agents and combinations. Understanding the results to date and determining what is working and what combinations are not working will be important to refine our understanding of immunity in patients with cancer. Questions that remain unanswered include: What is the rationale for the multiple immuno-oncology (IO) combinations being tested in the clinic, how do cancers adapt and resist T cell attack, and can we better understand the tumor microenvironment, thus paving the way for new approaches to cancer therapy. New analyses of patient-derived samples provide information on adaptive and genetic resistance mechanisms to immunotherapy. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system. Participants will leave the conference with an understanding of how the advancement of cancer biology will be influenced by a better comprehension of tumor immunology.

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.


custom image
custom image
custom image
custom image
custom image
custom image
custom image
custom image
custom image
custom image

Program Details

Keynote Speaker

Anthony S. Fauci, MD
Ton Schumacher, PhD
Netherlands Cancer Institute
T Cell Activity in the Tumor Microenvironment

Live ePanel Disucssion

Panel Discusion TBD

Editors Attending This Meeting

Editors TBD 

Speaking at this eSymposia

Program TBD

Neil P. King
University of Washington, USA
Structure-Based Design of Novel Nanoparticle Vaccine Platforms

Barney S. Graham
NIAID, National Institutes of Health, USA
Immunogen Design Strategies for Covid, RSV, Influenza and Other Enveloped Viruses

Gabriel D. Victora
Rockefeller University, USA
Clonal and Cellular Dynamics in Germinal Centers

Robert A. Seder
NIAID, National Institutes of Health, USA
Immunity After Intravenous Delivery of Antigens

Federica Sallusto
Università della Svizzera Italiana & ETH Zurich
Antigen Specific T Cell Diversity

Yasmine Belkaid
NIAID, National Institutes of Health, USA
Microbiome and Immunity

Galit Alter
Ragon Institute of MGH, MIT, and Harvard, USA
System Serology

Antonio Lanzavecchia
Institute for Research in Biomedicine, Switzerland
Human Monoclonals for Covid Passive Immunization and Antigen Discovery

Hedda Wardemann
German Cancer Research Center, Germany
Dissecting Antibody Responses to Plasmodium Falciparum Circumsporozoite Protein for the Development of a Malaria Vaccine

Catherine Ju-Ying Wu
Dana-Farber Cancer Institute, USA
Vaccines Against Tumor Neoantigens

Richard Hatchett
Coalition for Epidemic Preparedness Innovations, CEPI, UK
CEPI approach to emerging infections

Rino Rappuoli
GlaxoSmithKline Vaccines, Italy
Transforming Vaccinology
Included in Registration